Last reviewed · How we verify
NCT07350512
Investigating the Acute Effects of Increasing Alanine Exposure in Healthy Participants
NA trial testing alanine in Glucose Metabolism in 15 participants. Not yet recruiting.
30 September 2026
Quick facts
| Lead sponsor | Nicolai Jacob Wewer Albrechtsen |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 15 |
| Start date | 20 January 2026 |
| Primary completion | 30 September 2026 |
| Estimated completion | 20 January 2027 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- alanine (ALANINE) — full drug profile →
Conditions studied
- Glucose Metabolism — all drugs for Glucose Metabolism →
- Glucagon — all drugs for Glucagon →
Sponsor
Nicolai Jacob Wewer Albrechtsen
Who can join
Adults 25 to 70, any sex, with Glucose Metabolism or Glucagon. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study the investigators will investigate the acute effects of increasing alanine exposure on metabolic parameters in healthy participants. Participants will participate in one study day. After initial baseline blood samples, a three-hour intravenous infusion with glucagon will be initiated. The infusion rate will be increased every 30 minutes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07350512
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of alanine
Trials testing the same drug.
- NCT06881472 — The Separate and Combined Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Subject · NA · active not recruiting
Other recruiting trials for Glucose Metabolism
Currently open trials in the same condition.
- NCT07020741 — Stable Isotopes- Adults With Obesity · NA · recruiting
- NCT06700525 — StandUPTV Habits: Feasibility Trial for Maintaining Reductions in Sedentary Screen Time · NA · recruiting
- NCT05216042 — GENESIS: Genotype Guided - Natriuretic Peptides - Cardiometabolic Health Study · NA · recruiting
Other Nicolai Jacob Wewer Albrechtsen trials
Trials by the same sponsor.
- NCT06921824 — Investigating the Acute Effects of Increasing Glucagon Exposure in Healthy Participants · NA · completed
- NCT06647368 — Development of a Non-invasive Method for Quantifying Cerebral Glucose Metabolism for Studying the Effect of Glucagon in · NA · recruiting
- NCT03717688 — The Effects of Neprilysin on Glucagon-like Peptide-1 · Phase 4 · completed
- NCT03520062 — The Effect of Liraglutide on Pancreatic Hormones and Its Size · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07350512 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nicolai Jacob Wewer Albrechtsen
- Last refreshed: 20 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07350512.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing